In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and superior in reducing sweat chloride compared to TRIKAFTA Approximately 3,800 people in Canada are now eligible for ALYFTREK, with up to 60 people… Read More
Canada’s Royal Columbian Hospital (British Columbia, Canada) completes a 291-patient pilot study in the intensive care unit (ICU) – world’s first use of nasal photodisinfection in the ICU. ICU patients… Read More
Eyam Health, a Canadian biotech, and Medicines for Malaria Venture (MMV) will work together to develop new cost-effective next-generation monoclonal antibody-based antimalarials, using Eyam’s advanced biologics technology. The partnership aims to… Read More
New indication supported by the MANDARA trial, which showed 58% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids MISSISSAUGA, ON – Health Canada has granted… Read More
VANCOUVER, BC – Eyam Health announced the advancement of its partnership with a leading animal health company, entering the next phase of a joint development program focused on antibody-based therapeutics… Read More
